Intravenous Immunoglobulins, Human
ApprovedSmall molecule
Intravenous Immunoglobulins, Human is one of 7 small molecule programs targeting Stiff-Person syndrome. It is currently in Approved.
2
Indications
3
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
4 competitors in Guillain-Barre Syndrome
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Soliris
AstraZenecaPhase 3
Intravenous Immunoglobulins, Human
MMayo Clinic
Approved
Asceniv
CSL BehringPreclinical
Immunoglobulin
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Guillain-Barre syndrome1 trial
Early and Late Prognosis in Patients With Guillain-Barre Syndrome
Unknown status·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT06041451·450 enrolled
Stiff-Person syndrome1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMayo Clinic